Here, we identify and study the underlying molecular mechanisms of impaired synaptic transmission in a patient with CMS harboring two novel missense mutations in MUSK (p.Cys317Arg and p.Ala617Val), so that, based on the molecular findings, an appropriate treatment strategy could be pursued. This evidence concerns the gene MUSK and congenital myasthenic syndrome.